← Leaderboards
Changning Wang
Massachusetts General Hospital
$11,415,964
Attributed
$20,394,064
Total exposure
20
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,394,064 · 20
By mechanism
R01$5,332,695 · 3
RF1$4,181,352 · 2
R61$4,131,086 · 2
R33$2,568,139 · 2
R21$1,921,335 · 4
R03$1,483,102 · 6
Top collaborators
- Can Martin Zhang13 shared
- Stephen N. Gomperts6 shared
- Shiqian Shen4 shared
- Timothy T Houle1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Can Martin Zhang$10,046,963
- Boris Dominik Juelg$12,991,342
- Robert L Martuza$21,256,149
- Jolan Eszter Walter$2,915,657
- Fotis Constantine Kafatos$1,485,257
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBindingBrainPositron-Emission TomographyRadiotracerFunctional DisorderIn VivoS DiseaseImageAnimalsResponseNonhuman PrimateImaging ProbeFda ApprovedReportingRodentEnzymesHistone DeacetylaseDementiaBaseEpigenetic ProcessDesignMagnetic Resonance ImagingTherapeutic Target
Grant awards (33)
Imaging epigenetic dysregulation in the Lewy body dementias with [11C]Martinostat$814,349
R01 · FY2025 · AG
Molecular imaging of RIPK1/necroptosis as a key biomarker in Alzheimer's disease$791,560
R33 · FY2025 · AG · contact PI
New epigenetic inhibitors for Alzheimer's disease treatment$790,816
R01 · FY2025 · AG · contact PI
Gut Microbiota Underlies the Heterogeneity of Aging Brain's Susceptibility to Postoperative Delirium$622,824
R01 · FY2025 · AG
Imaging epigenetic dysregulation in the Lewy body dementias with [11C]Martinostat$827,629
R01 · FY2024 · AG
New epigenetic inhibitors for Alzheimer's disease treatment$806,956
R01 · FY2024 · AG · contact PI
Gut Microbiota Underlies the Heterogeneity of Aging Brain's Susceptibility to Postoperative Delirium$648,974
R01 · FY2024 · AG
BET-BD1 Selective Neuroimaging probes for Alzheimer's disease research$2,442,345
RF1 · FY2023 · AG · contact PI
Imaging epigenetic dysregulation in the Lewy body dementias with [11C]Martinostat$821,147
R01 · FY2023 · AG
Inhibiting RIPK1 with Necrostatin-1 for Safe and Effective Pain Treatment$1,633,790
R61 · FY2022 · NS
Molecular imaging of RIPK1/necroptosis as a key biomarker in Alzheimer's disease$832,432
R61 · FY2022 · AG · contact PI
Investigation of sirtuin 1 expression in mice model of Alzheimer's disease over age$323,760
R03 · FY2022 · AG · contact PI
Gut Microbiota Underlies the Heterogeneity of Aging Brain's Susceptibility to Postoperative Delirium$1,739,007
RF1 · FY2021 · AG
Molecular imaging of RIPK1/necroptosis as a key biomarker in Alzheimer's disease$832,432
R61 · FY2021 · AG · contact PI
Imaging Epigenetic Mechanisms in the Lewy Body Dementias with [11C]Martinostat$776,355
R56 · FY2021 · AG
A new PET neuroimaging probe for sigma 1 receptor$250,640
R03 · FY2021 · DA · contact PI
Molecular imaging of RIPK1/necroptosis as a key biomarker in Alzheimer's disease$832,432
R61 · FY2020 · AG · contact PI
Epigenetic Mechanisms in Alcohol Use Disorder quantified by non-invasive PET imaging$592,193
R33 · FY2020 · AA · contact PI
Selective PET imaging probes targeting BD1 of N-terminal bromodomains$249,280
R03 · FY2020 · DA · contact PI
Molecular imaging of PS1/gamma-secretase and analysis of Alzheimer's disease.$208,640
R21 · FY2020 · AG
Non-invasive imaging of T cells$82,960
R03 · FY2020 · EB · contact PI
Epigenetic Mechanisms in Alcohol Use Disorder quantified by non-invasive PET imaging$592,193
R33 · FY2019 · AA · contact PI
Molecular imaging of PS1/gamma-secretase and analysis of Alzheimer's disease.$250,640
R21 · FY2019 · AG
Development of brain-penetrant HDAC6-selective inhibitors$250,353
R21 · FY2019 · MH · contact PI
Developing new PET imaging probes for orexin 1 receptors$241,800
R03 · FY2019 · DA · contact PI
Imaging Epigenetic Mechanisms in Parkinson's Disease with [11C]Martinostat$210,625
R21 · FY2019 · NS
Non-invasive imaging of T cells$82,960
R03 · FY2019 · EB · contact PI
Epigenetic Mechanisms in Alcohol Use Disorder quantified by non-invasive PET imaging$592,193
R33 · FY2018 · AA · contact PI
Imaging Epigenetic Mechanisms in Parkinson's Disease with [11C]Martinostat$252,750
R21 · FY2018 · NS
Non-invasive neuroimaging of sirtuin 1 using PET$251,702
R03 · FY2018 · EB · contact PI
Development of brain-penetrant HDAC6-selective inhibitors$208,228
R21 · FY2018 · MH · contact PI
Epigenetic Mechanisms in Alcohol Use Disorder quantified by non-invasive PET imaging$262,114
R21 · FY2017 · AA · contact PI
Epigenetic Mechanisms in Alcohol Use Disorder quantified by non-invasive PET imaging$277,985
R21 · FY2016 · AA · contact PI